Scientists who want a say in the future of their inventions are once again moving from academia to the C-suite ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Key regulatory milestones and financial updates position Sangamo Therapeutics Inc (SGMO) for potential growth despite funding ...

RICHMOND, Calif., November 12, 2024 -- ( BUSINESS WIRE )--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial ...

In its third-quarter 2024 earnings report, Sangamo announced significant achievements, including a regulatory pathway for accelerated approval of a Fabry disease treatment and promising collaborative ...

Aris has signed Emmy-nominated Indian-American director Zoe Malhotra, marking her first exclusive representation deal in the ...

Reports Q3 revenue $29.4M, consensus $26.55M. “This is a pivotal time for Sangamo (SGMO) as we build upon our recent strong momentum with ...

Wyatte Grantham-philips, The Associated Press Nov 12, 2024 9:40 AM Nov 12, 2024 10:05 AM FILE - 23andMe CEO Anne Wojcicki ...

In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the ...

NEW YORK — 23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics ...